Koninklijke Philips (PHIA) Q2 2025 earnings summary

Executive summary

• Order intake grew 6% year-over-year, with group sales at €4.3 billion (up 1%), led by Personal Health, while Diagnosis & Treatment and Connected Care saw slight declines; margin expansion was driven by innovation, productivity, and favorable mix.

• Adjusted EBITA/EBITDA margin rose 130 basis points to 12.4%, supported by innovation, productivity, and product mix.

• Free cash flow increased to €230 million, reflecting disciplined working capital management and lower Respironics-related payments.

• Full-year 2025 outlook for comparable sales growth reiterated at 1%-3%; adjusted EBITA/EBITDA margin guidance raised to 11.3%-11.8%; free cash flow guidance increased to €0.2–0.4 billion.

• Major AI-powered product launches and a significant partnership with Indonesia's Ministry of Health expanded access to advanced therapies.

Financial highlights

• Q2 2025 sales: €4,338 million (up 1% year-over-year); adjusted EBITA: €540 million (12.4% margin); free cash flow: €230 million.

• Adjusted diluted EPS from continuing operations was €0.36, up 20% year-over-year.

• Gross margin strengthened by innovation and productivity, partially offset by cost inflation and currency headwinds.

• Year-end cash at €1.8 billion; net debt at €6.6 billion; leverage ratio stable at 2.2x net debt-to-adjusted EBITDA.

• Group working capital as % of LTM sales: 14.5% in Q2 2025, down from 15.5% in Q2 2024.

Outlook and guidance

• Full-year comparable sales growth outlook maintained at 1%-3%, with stronger weighting in Q4 and sequential improvement expected.

• Adjusted EBITA/EBITDA margin guidance raised by 50 basis points to 11.3%-11.8% for 2025, reflecting lower-than-expected tariffs.

• Free cash flow for 2025 now expected at €0.2–0.4 billion, up from slightly positive previously, including Respironics settlement payout.

• Tariff impact for 2025 estimated at €150–200 million, down €100 million from prior estimate.

• Outlook excludes ongoing Respironics-related proceedings and DOJ investigation.